SUPPLEMENT
Q4 2024 — Financial disclosures
Q4 2024PDF · 10 pages1.1 MB
Merck & Co., Inc. Financial Highlights Package Fourth Quarter 2024 Table of Contents Table 1: GAAP P&L...................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter................2 Table 2a: GAAP to Non-GAAP Reconciliation 4Q24 and Dec YTD 24.......3 Table 2b: GAAP to Non-GAAP Reconciliation 4Q23 and Dec YTD 23.......4 Table 3: Sales - Current Year and Prior Year by Quarter..........................5 Table 3a: Sales – U.S. / International 4Q24................................................6 Table 3b: Sales – U.S. / International Dec YTD 24.. ..................................7 Table 3c: Sales – Pharmaceutical Geographic Split...................................8 Table 4: Other (Income) Expense ............................................................9 -- 1 of 10 -- Sales 15,624 $ 14,630 $ 7% 64,168 $ 60,115 $ 7% Costs, Expenses and Other Cost of sales 3,828 3,911 -2% 15,193 16,126 -6% Selling, general and administrative 2,864 2,804 2% 10,816 10,504 3% Research and development 4,585 9,628 -52% 17,938 30,531 -41% Restructuring costs 51 255 -80% 309 599 -48% Other (income) expense, net 126 78 62% (24) 466 * Income (Loss) Before Taxes 4,170 (2,046) * 19,936 1,889 * Income Tax Provision (Benefit) 425 (821) 2,803 1,512 Net Income (Loss) 3,745 (1,225) * 17,133 377 * Less: Net Income Attributable to Noncontrolling Interests 2 1 16 12 Net Income (Loss) Attributable to Merck & Co., Inc. 3,743 $ (1,226) $ * 17,117 $ 365 $ * Earnings (Loss) per Common Share Assuming Dilution (1) 1.48 $ (0.48) $ * 6.74 $ 0.14 $ * Average Shares Outstanding Assuming Dilution (1) 2,537 2,533 2,541 2,547 Tax Rate 10.2% 40.1% 14.1% 80.0% * 100% or greater (1) Because the company recorded a net loss in the fourth quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. GAAP % Change Full Year 2024 Full Year 2023 GAAP % Change 4Q24 4Q23 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 1 -- 2 of 10 -- Sales 15,775 $ 16,112 $ 16,657 $ 15,624 $ 64,168 $ 14,487 $ 15,035 $ 15,962 $ 14,630 $ 60,115 $ 7% 7% Costs, Expenses and Other Cost of sales 3,540 3,745 4,080 3,828 15,193 3,926 4,024 4,264 3,911 16,126 -2% -6% Selling, general and administrative 2,483 2,739 2,731 2,864 10,816 2,479 2,702 2,519 2,804 10,504 2% 3% Research and development 3,992 3,500 5,862 4,585 17,938 4,276 13,321 3,307 9,628 30,531 -52% -41% Restructuring costs 123 80 56 51 309 67 151 126 255 599 -80% -48% Other (income) expense, net (33) 42 (162) 126 (24) 89 172 126 78 466 62% * Income (Loss) Before Taxes 5,670 6,006 4,090 4,170 19,936 3,650 (5,335) 5,620 (2,046) 1,889 * * Income Tax Provision (Benefit) 903 545 929 425 2,803 825 637 870 (821) 1,512 Net Income (Loss) 4,767 5,461 3,161 3,745 17,133 2,825 (5,972) 4,750 (1,225) 377 * * Less: Net Income Attributable to Noncontrolling Interests 5 6 4 2 16 4 3 5 1 12 Net Income (Loss) Attributable to Merck & Co., Inc. 4,762 $ 5,455 $ 3,157 $ 3,743 $ 17,117 $ 2,821 $ (5,975) $ 4,745 $ (1,226) $ 365 $ * * Earnings (Loss) per Common Share Assuming Dilution (1) 1.87 $ 2.14 $ 1.24 $ 1.48 $ 6.74 $ 1.11 $ (2.35) $ 1.86 $ (0.48) $ 0.14 $ * * Average Shares Outstanding Assuming Dilution (1) 2,544 2,544 2,541 2,537 2,541 2,551 2,539 2,546 2,533 2,547 Tax Rate 15.9% 9.1% 22.7% 10.2% 14.1% 22.6% -11.9% 15.5% 40.1% 80.0% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. Full Year % Change Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) 4Q (1) Because the company recorded a net loss in the second quarter and the fourth quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. 2024 2Q 3Q 4Q Full Year 1Q 1Q 2Q 3Q 4Q Full Year 2023 2 -- 3 of 10 -- Fourth Quarter Cost of sales 3,828 $ 701 121 822 3,006 $ Selling, general and administrative 2,864 29 16 45 2,819 Research and development 4,585 12 (1) 11 4,574 Restructuring costs 51 51 51 – Other (income) expense, net 126 (31) 152 121 5 Income Before Taxes 4,170 (711) (187) (152) (1,050) 5,220 Income Tax Provision (Benefit) 425 (111) (3) (17) (3) (33) (3) (260) (4) (421) 846 Net Income 3,745 (600) (170) (119) 260 (629) 4,374 Net Income Attributable to Merck & Co., Inc. 3,743 (600) (170) (119) 260 (629) 4,372 Earnings per Common Share Assuming Dilution 1.48 $ (0.23) (0.07) (0.04) 0.10 (0.24) 1.72 $ Tax Rate 10.2% 16.2% Full Year Cost of sales 15,193 $ 2,409 495 2,904 12,289 $ Selling, general and administrative 10,816 117 83 200 10,616 Research and development 17,938 72 1 73 17,865 Restructuring costs 309 309 309 – Other (income) expense, net (24) (79) 45 (34) 10 Income Before Taxes 19,936 (2,519) (888) (45) (3,452) 23,388 Income Tax Provision (Benefit) 2,803 (461) (3) (135) (3) (10) (3) (519) (4) (1,125) 3,928 Net Income 17,133 (2,058) (753) (35) 519 (2,327) 19,460 Net Income Attributable to Merck & Co., Inc. 17,117 (2,058) (753) (35) 519 (2,327) 19,444 Earnings per Common Share Assuming Dilution 6.74 $ (0.81) (0.30) (0.01) 0.21 (0.91) 7.65 $ Tax Rate 14.1% 16.8% Only the line items that are affected by non-GAAP adjustments are shown. Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Additionally, research and development expenses for the full year includes Animal Health intangible asset impairment charges. Amounts included in other (income) expense, net, primarily reflect royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. (4) Represents benefits recorded in the fourth quarter and full year due to reductions in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to federal income tax return years. The benefit recognized in the fourth quarter relates to the 2020 federal tax return year and the benefit recognized for the full year relates to both the 2020 and 2019 federal tax return years. MERCK & CO., INC. FOURTH QUARTER AND FULL YEAR 2024 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Table 2a Certain Other Items Adjustment Subtotal Non-GAAP 3 -- 4 of 10 -- Fourth Quarter Cost of sales 3,911 $ 454 117 571 3,340 $ Selling, general and administrative 2,804 24 29 53 2,751 Research and development 9,628 790 790 8,838 Restructuring costs 255 255 255 – Other (income) expense, net 78 (35) (61) (96) 174 Loss Before Taxes (2,046) (1,233) (401) 61 (1,573) (473) Income Tax Provision (Benefit) (821) (227) (4) (67) (4) 13 (4) (281) (540) Net (Loss) Income (1,225) (1,006) (334) 48 (1,292) 67 Net (Loss) Income Attributable to Merck & Co., Inc. (1,226) (1,006) (334) 48 (1,292) 66 (Loss) Earnings per Common Share Assuming Dilution (5) (0.48) $ (0.40) (0.13) 0.02 (0.51) 0.03 $ Tax Rate 40.1% 114.2% Full Year Cost of sales 16,126 $ 2,018 211 2,229 13,897 $ Selling, general and administrative 10,504 86 122 208 10,296 Research and development 30,531 819 1 820 29,711 Restructuring costs 599 599 599 – Other (income) expense, net 466 (47) (279) 573 (3) 247 219 Income Before Taxes 1,889 (2,876) (933) 279 (573) (4,103) 5,992 Income Tax Provision (Benefit) 1,512 (476) (4) (155) (4) 60 (4) (60) (4) (631) 2,143 Net Income 377 (2,400) (778) 219 (513) (3,472) 3,849 Net Income Attributable to Merck & Co., Inc. 365 (2,400) (778) 219 (513) (3,472) 3,837 Earnings per Common Share Assuming Dilution 0.14 $ (0.94) (0.31) 0.08 (0.20) (1.37) 1.51 $ Tax Rate 80.0% 35.8% Only the line items that are affected by non-GAAP adjustments are shown. (5) Because the company recorded a net loss in the fourth quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non- GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect a $779 million in-process research and development (IPR&D) impairment charge related to gefapixant and expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture. Additionally, other (income) expense, net, for the full year includes a $37 million loss on the sale of a business. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation. (4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Adjustment Subtotal Non-GAAP MERCK & CO., INC. FOURTH QUARTER AND FULL YEAR 2023 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items 4 -- 5 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2024 2023 4Q Full Year 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $15,775 $16,112 $16,657 $15,624 $64,168 $14,487 $15,035 $15,962 $14,630 $60,115 7 9 7 10 PHARMACEUTICAL 14,006 14,408 14,943 14,042 57,400 12,721 13,457 14,263 13,141 53,583 7 8 7 10 Oncology Keytruda 6,947 7,270 7,429 7,836 29,482 5,795 6,271 6,338 6,608 25,011 19 21 18 22 Alliance Revenue – Lynparza (2) 292 317 337 365 1,311 275 310 299 315 1,199 16 18 9 11 Alliance Revenue – Lenvima (2) 255 249 251 255 1,010 232 242 260 226 960 13 14 5 6 Welireg 85 126 139 160 509 42 50 54 72 218 122 123 133 133 Alliance Revenue – Reblozyl (3) 71 90 100 110 371 43 47 52 70 212 58 58 75 75 Vaccines (4) Gardasil/Gardasil 9 2,249 2,478 2,306 1,550 8,583 1,972 2,458 2,585 1,871 8,886 -17 -18 -3 -2 ProQuad/M-M-R II/Varivax 570 617 703 594 2,485 528 582 713 545 2,368 9 9 5 5 Vaxneuvance 219 189 239 161 808 106 168 214 176 665 -9 -9 22 23 RotaTeq 216 163 193 139 711 297 131 156 185 769 -25 -25 -8 -7 Pneumovax 23 61 59 68 74 263 96 92 140 85 412 -12 -12 -36 -34 Hospital Acute Care Bridion 440 455 420 449 1,764 487 502 424 429 1,842 5 5 -4 -3 Prevymis 174 188 208 215 785 129 143 157 175 605 23 23 30 33 Dificid 73 92 96 79 340 65 76 74 87 302 -9 -9 13 13 Zerbaxa 56 62 64 70 252 50 54 53 61 218 14 16 16 18 Noxafil 56 45 41 36 177 60 55 51 46 213 -23 -17 -17 -8 Cardiovascular Winrevair 70 149 200 419 - - - - Alliance Revenue - Adempas/Verquvo (5) 98 106 102 109 415 99 68 92 108 367 1 1 13 13 Adempas (6) 70 72 72 73 287 59 65 65 66 255 11 9 12 14 Virology Lagevrio 350 110 383 121 964 392 203 640 193 1,428 -37 -37 -33 -28 Isentress/Isentress HD 111 89 102 92 394 123 136 119 105 483 -13 -7 -18 -14 Delstrigo 56 60 65 69 249 44 50 54 54 201 28 29 24 26 Pifeltro 42 39 42 40 163 34 38 37 33 142 20 20 15 15 Neuroscience Belsomra 46 53 78 45 222 56 63 58 54 231 -17 -17 -4 1 Immunology Simponi 184 172 189 543 180 180 179 171 710 N/M N/M -24 -23 Remicade 39 35 41 114 51 48 45 43 187 N/M N/M -39 -36 Diabetes (7) Januvia 419 405 278 232 1,334 551 511 581 547 2,189 -58 -56 -39 -36 Janumet 251 224 204 255 935 329 354 255 240 1,177 7 11 -21 -16 Other Pharmaceutical (8) 576 573 644 713 2,510 626 560 568 576 2,333 25 25 8 10 ANIMAL HEALTH 1,511 1,482 1,487 1,397 5,877 1,491 1,456 1,400 1,278 5,625 9 13 4 8 Livestock 850 837 886 889 3,462 849 807 874 808 3,337 10 14 4 9 Companion Animal 661 645 601 508 2,415 642 649 526 470 2,288 8 10 6 7 Other Revenues (9) 258 222 227 185 891 275 122 299 211 907 -13 3 -2 4 N/M - Not Meaningful Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (7) Total Diabetes sales were $745 million, $715 million, $592 million and $546 million in the first, second, third and fourth quarter of 2024, respectively, and $950 million, $951 million, $924 million and $876 million in the first, second, third and fourth quarter of 2023, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $61 million, $15 million, $15 million and $15 million in the first, second, third and fourth quarter of 2024, respectively, and $51 million, $3 million and $65 million in the first, second and third quarter of 2023, respectively. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $3,424 million, $3,656 million, $3,675 million and $2,693 million in the first, second, third and fourth quarter of 2024, respectively, and $3,133 million, $3,557 million, $4,002 million and $2,962 million in the first, second, third and fourth quarter of 2023, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. 5 -- 6 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES FOURTH QUARTER 2024 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International 4Q 2024 4Q 2023 % Change 4Q 2024 4Q 2023 % Change 4Q 2024 4Q 2023 % Change TOTAL SALES (1) $15,624 $14,630 7 $8,188 $7,088 16 $7,436 $7,542 -1 PHARMACEUTICAL 14,042 13,141 7 7,728 6,698 15 6,314 6,443 -2 Oncology Keytruda 7,836 6,608 19 4,841 3,972 22 2,996 2,636 14 Alliance Revenue – Lynparza (2) 365 315 16 177 168 5 187 147 28 Alliance Revenue – Lenvima (2) 255 226 13 182 181 1 73 45 63 Welireg 160 72 122 146 68 114 14 4 * Alliance Revenue – Reblozyl (3) 110 70 58 88 60 47 22 10 124 Vaccines (4) Gardasil/Gardasil 9 1,550 1,871 -17 380 365 4 1,170 1,506 -22 ProQuad/M-M-R II/Varivax 594 545 9 419 402 4 175 143 23 Vaxneuvance 161 176 -9 64 138 -53 96 38 153 RotaTeq 139 185 -25 84 112 -25 55 73 -25 Pneumovax 23 74 85 -12 19 22 -13 55 62 -12 Hospital Acute Care Bridion 449 429 5 382 315 21 67 113 -41 Prevymis 215 175 23 106 78 36 109 98 12 Dificid 79 87 -9 72 75 -4 7 12 -42 Zerbaxa 70 61 14 40 33 23 30 28 4 Noxafil 36 46 -23 -2 4 -149 37 43 -12 Cardiovascular Winrevair 200 - 192 - 9 - Alliance Revenue - Adempas/Verquvo (5) 109 108 1 105 102 3 5 6 -27 Adempas (6) 73 66 11 73 66 11 Virology Lagevrio 121 193 -37 32 10 * 88 183 -52 Isentress/Isentress HD 92 105 -13 38 50 -23 53 56 -4 Delstrigo 69 54 28 14 12 19 55 42 30 Pifeltro 40 33 20 26 23 16 13 10 29 Neuroscience Belsomra 45 54 -17 19 21 -12 26 33 -20 Immunology Simponi 171 N/M 171 N/M Remicade 43 N/M 43 N/M Diabetes (7) Januvia 232 547 -58 41 309 -87 191 239 -20 Janumet 255 240 7 91 41 122 164 198 -17 Other Pharmaceutical (8) 713 576 25 172 137 26 544 438 24 ANIMAL HEALTH 1,397 1,278 9 444 387 15 953 891 7 Livestock 889 808 10 203 158 28 686 649 6 Companion Animal 508 470 8 241 229 5 267 242 11 Other Revenues (9) 185 211 -13 16 3 * 169 208 -19 *200% or greater N/M - Not Meaningful (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $546 million and $876 million on a global basis in the fourth quarter of 2024 and 2023, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $15 million on a global basis in the fourth quarter of 2024. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,693 million and $2,962 million on a global basis in the fourth quarter of 2024 and 2023, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 6 -- 7 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES FULL YEAR 2024 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b Global U.S. International Full Year 2024 Full Year 2023 % Change Full Year 2024 Full Year 2023 % Change Full Year 2024 Full Year 2023 % Change TOTAL SALES (1) $64,168 $60,115 7 $32,277 $28,480 13 $31,891 $31,635 1 PHARMACEUTICAL 57,400 53,583 7 30,290 26,539 14 27,110 27,044 - Oncology Keytruda 29,482 25,011 18 17,872 15,114 18 11,610 9,897 17 Alliance Revenue – Lynparza (2) 1,311 1,199 9 626 607 3 685 592 16 Alliance Revenue – Lenvima (2) 1,010 960 5 705 657 7 305 303 1 Welireg 509 218 133 466 209 123 43 10 * Alliance Revenue – Reblozyl (3) 371 212 75 303 168 80 68 43 56 Vaccines (4) Gardasil/Gardasil 9 8,583 8,886 -3 2,425 2,083 16 6,158 6,803 -9 ProQuad/M-M-R II/Varivax 2,485 2,368 5 1,919 1,837 4 566 531 7 Vaxneuvance 808 665 22 461 561 -18 347 103 * RotaTeq 711 769 -8 472 493 -4 239 276 -13 Pneumovax 23 263 412 -36 56 127 -56 207 285 -27 Hospital Acute Care Bridion 1,764 1,842 -4 1,401 1,156 21 363 686 -47 Prevymis 785 605 30 371 264 41 414 341 21 Dificid 340 302 13 303 274 10 37 28 34 Zerbaxa 252 218 16 146 119 23 106 100 7 Noxafil 177 213 -17 7 32 -78 170 181 -6 Cardiovascular Winrevair 419 - 408 - 11 - Alliance Revenue - Adempas/Verquvo (5) 415 367 13 388 350 11 27 16 65 Adempas (6) 287 255 12 287 255 12 Virology Lagevrio 964 1,428 -33 176 10 * 787 1,418 -44 Isentress/Isentress HD 394 483 -18 185 215 -14 209 268 -22 Delstrigo 249 201 24 56 49 14 193 152 27 Pifeltro 163 142 15 113 101 12 50 41 22 Neuroscience Belsomra 222 231 -4 72 81 -11 150 150 - Immunology Simponi 543 710 -24 543 710 -24 Remicade 114 187 -39 114 187 -39 Diabetes (7) Januvia 1,334 2,189 -39 469 1,151 -59 865 1,039 -17 Janumet 935 1,177 -21 161 223 -28 774 954 -19 Other Pharmaceutical (8) 2,510 2,333 8 729 658 11 1,782 1,675 6 ANIMAL HEALTH 5,877 5,625 4 1,861 1,804 3 4,016 3,821 5 Livestock 3,462 3,337 4 732 700 5 2,729 2,637 3 Companion Animal 2,415 2,288 6 1,129 1,104 2 1,287 1,184 9 Other Revenues (9) 891 907 -2 126 137 -8 765 770 -1 *200% or greater (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $2,599 million and $3,701 million on a global basis for December YTD 2024 and 2023, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $106 million and $118 million on a global basis for December YTD 2024 and 2023, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $13,448 million and $13,654 million on a global basis for December YTD 2024 and 2023, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 7 -- 8 of 10 -- MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c 2024 2023 % Change 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year 4Q Full Year TOTAL PHARMACEUTICAL $14,006 $14,408 $14,943 $14,042 $57,400 $12,721 $13,457 $14,263 $13,141 $53,583 7 7 United States 6,936 7,399 8,227 7,728 30,290 6,117 6,570 7,153 6,698 26,539 15 14 % Pharmaceutical Sales 49.5% 51.4% 55.1% 55.0% 52.8% 48.1% 48.8% 50.1% 51.0% 49.5% Europe (1) 2,555 2,572 2,620 2,498 10,246 2,326 2,401 2,497 2,491 9,715 - 5 % Pharmaceutical Sales 18.2% 17.9% 17.5% 17.8% 17.9% 18.3% 17.8% 17.5% 19.0% 18.1% China 1,744 1,790 996 864 5,394 1,694 1,887 1,674 1,456 6,710 -41 -20 % Pharmaceutical Sales 12.5% 12.4% 6.7% 6.2% 9.4% 13.3% 14.0% 11.7% 11.1% 12.5% Japan 802 664 919 813 3,199 737 652 1,062 629 3,081 29 4 % Pharmaceutical Sales 5.7% 4.6% 6.2% 5.8% 5.6% 5.8% 4.8% 7.4% 4.8% 5.7% Latin America 601 661 730 680 2,672 470 566 696 596 2,328 14 15 % Pharmaceutical Sales 4.3% 4.6% 4.9% 4.8% 4.7% 3.7% 4.2% 4.9% 4.5% 4.3% Asia Pacific (other than China and Japan) 580 595 669 612 2,457 703 705 636 616 2,661 -1 -8 % Pharmaceutical Sales 4.1% 4.1% 4.5% 4.4% 4.3% 5.5% 5.2% 4.5% 4.7% 5.0% Eastern Europe/Middle East/Africa 395 353 400 348 1,495 381 370 301 299 1,351 16 11 % Pharmaceutical Sales 2.8% 2.4% 2.7% 2.5% 2.6% 3.0% 2.7% 2.1% 2.3% 2.5% Canada 138 143 133 144 558 141 127 133 138 540 4 3 % Pharmaceutical Sales 1.0% 1.0% 0.9% 1.0% 1.0% 1.1% 0.9% 0.9% 1.1% 1.0% Other 255 231 249 355 1,089 152 179 111 218 658 63 66 % Pharmaceutical Sales 1.9% 1.6% 1.5% 2.5% 1.7% 1.2% 1.6% 0.9% 1.5% 1.4% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 8 -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 4Q24 4Q23 Full Year 2024 Full Year 2023 Interest income (146) $ (70) $ (415) $ (365) $ Interest expense 328 310 1,271 1,146 Exchange losses 49 162 227 370 Loss (income) from investments in equity securities, net (1) 156 (99) (14) (340) Net periodic defined benefit plan (credit) cost other than service cost (157) (134) (633) (498) Other, net (104) (91) (460) 153 Total 126 $ 78 $ (24) $ 466 $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 9 -- 10 of 10 --